The abstract is read at the publisher; the summary is JClub's.
B7-H3-targeted CAR-engineered NK cells show antigen-specific cytotoxicity against atypical teratoid/rhabdoid tumors and prolong survival in orthotopic xenograft mouse models.
- Why it matters: ATRTs in infants have low survival and limited options, and treatment-related morbidity remains a major concern; targeting the commonly overexpressed antigen B7-H3 could improve outcomes.
- What they did: The study built a variable-affinity library of B7-H3 CARs, transduced primary healthy donor NK cells, confirmed B7-H3 on ATRT lines, used in vitro co-culture killing assays, and tested intratumoral or ICV delivery in orthotopic xenografts.
- The result: CAR-NK killing was target-specific and was abolished by B7-H3 knockout; intratumoral dosing in CHLA-06 orthotopic xenografts eliminated tumor cells and prolonged survival, and ICV dosing against BT12 CNS-distributed tumors significantly improved survival.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.